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Abstract
Posttranslational modification of histones by biotinylation can be catalyzed by both biotinidase (BTD) and holocarboxylase synthetase.
Biotinylation of histones is an important epigenetic mechanism to regulate gene expression, DNA repair, and chromatin remodeling. The role
of BTD in histone biotinylation is somewhat ambiguous, given that BTD also catalyzes removal of the biotin tag from histones. Here, we
sought to develop BTD inhibitors for future studies of the role of BTD in altering chromatin structure. We adopted an existing colorimetric
BTD assay for use in a novel 96-well plate format to permit high-throughput screening of potential inhibitors. Biotin analogs were chemically
synthesized and tested for their ability to inhibit human BTD. Seven of these compounds inhibited BTD by 26–80%. Biotinyl-methyl
4-(amidomethyl)benzoate had the largest effect on BTD, causing an 80% inhibition at 1 mM concentration. Enzyme kinetics studies were
conducted to determine Vmax, Km and Ki for the seven inhibitors; kinetics were consistent with the hypothesis that biotinyl-methyl
4-(amidomethyl)benzoate and the other compounds acted by competitive inhibition of BTD. Finally, biotinyl-methyl 4-(amidomethyl)
benzoate did not affect biotin transport in human cells, suggesting specificity in regard to biotin-related processes.
© 2008 Published by Elsevier Inc.
Keywords: Biotinidase; Biotinyl-methyl 4-amidomethyl benzoate; Histones; Inhibitors

1. Introduction
Mammals contain two biotin-metabolizing enzymes,
namely, holocarboxylase synthetase (HCS) and biotinidase
(BTD). HCS is a cytoplasmic, mitochondrial, and nuclear
protein [1–3], whereas BTD is predominantly secreted into
serum [4,5] but can also be found in the cell nucleus [2,4]. HCS
catalyzes the covalent binding of biotin to a specific lysine
residue in apocarboxylases to produce holocarboxylases [6].
The classic function of BTD is to recycle biotin by hydrolyzing
the amide bond between biotin and lysine residues (biocytin)
in breakdown products of holocarboxylases [7].
Abbreviations: BTD, biotinidase; DMSO, dimethyl sulfoxide; HCS,
holocarboxylase synthetase; MCD, multiple carboxylase deficiency; PABA,
para-aminobenzoic acid.
⁎ Corresponding author. Tel.: +1 402 472 3270; fax: +1 402 472 1587.
E-mail address: jzempleni2@unl.edu (J. Zempleni).
0955-2863/$ – see front matter © 2008 Published by Elsevier Inc.
doi:10.1016/j.jnutbio.2007.11.002

Recently, it was proposed that both BTD and HCS also
catalyze the biotinylation of ε-amino groups in specific
lysine residues in histones [1,8–11]. Posttranslational
modifications of histones have distinct functions in chromatin metabolism. For example, trimethylation of K4 in histone
H3 is associated with transcriptional activation of genes,
whereas dimethylation of K9 in histone H3 is associated with
transcriptional silencing [12,13].
All five major classes of histones are targets for
biotinylation in human cells [10]. While the physiological
roles of histone biotinylation are under investigation, there is
increasing evidence that histone biotinylation plays a role in
DNA repair [14], gene silencing and heterochromatin
structures in human cells [15] and stress resistance and life
span in Drosophila [16,17]. Biotinylation of histones is
mediated by both HCS [1,16] and BTD [8], but evidence has
been provided that HCS is the dominant histone-biotinyl
ligase [16].
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Table 1
Inhibitors of BTD
Inhibitors

Structure
%
Inhibition a

Biotinyl anilide

55±0.1

Biotinyl allylamide 37±0.09

Biotinyl
N-methylanilide

26±0.05

Biotinyl methyl
80±0.02
4-(amidomethyl)
benzoate

Biotinyl
40±0.05
2-amido-pyridine

Biotinyl
4-amidophenyl
boronic acid

Biotinylation of histones is a reversible modification.
Ballard et al. [18] suggested that debiotinylation of histones
might be mediated by BTD. The regulation of BTD to favor
debiotinylation of histones over biotinylation of histones by
the same enzyme is unknown. A number of variables may
regulate the catalytic activity of BTD. First, the availability
of substrate might favor either biotinylation or debiotinylation of histones. For example, locally high concentrations of
biocytin might shift the reaction equilibrium toward
biotinylation of histones [8,19]. Second, proteins may
interact with BTD at the chromatin level, favoring either
biotinylation or debiotinylation of histones. Third, three
alternatively spliced variants of BTD have been identified
[20]. Theoretically, these variants may have unique functions
with regard to histone biotinylation. Fourth, BTD possesses
six glycosylation sites [21,22]; glycosylation of BTD might
affect its cellular location [23].
Our long-term goal is to identify the roles of BTD in
biotinylation and debiotinylation of histones. As a first step
toward this goal, we generated a first generation of synthetic
inhibitors of BTD, and we developed a 96-well plate assay
for high-throughput screening of putative BTD inhibitors.
Previous studies have proposed using biotin, di-isopropylfluorophosphate and thiol reagents such as p-chloromercuribenzoate as inhibitors of BTD [4]. These compounds are
of limited use for the following two reasons. First, diisopropylfluorophosphate and p-chloromercuribenzoate are
general inhibitors of enzymes as opposed to being specific
inhibitors of BTD. Second, simultaneous inhibition of BTD
in both cytoplasm and nucleus make it impossible to link
potential effects of low BTD activity to altered histone
debiotinylation in the nucleus as opposed to impaired biotin
recycling in the cytoplasm. The studies presented here lay
the groundwork for the development of second-generation
inhibitors that can be targeted directly to the nucleus to
interfere with histone debiotinylation without affecting
cytoplasmic events.

53±0.02

2. Materials and methods
2.1. BTD purification

Biotinyl
benzylamide

a

47±0.01

Percent inhibition compared with inhibitor-free control after 2 h
of incubation of BTD+Inhibitor+Substrate. Values are means±S.D.
(n=6; Pb.05 compared with inhibitor-free control).

Human plasma, which is known to contain high levels of
BTD activity [4], served as a source of BTD in this study.
Approximately 150 ml of human blood was collected through
venipuncture into heparinized containers. This study was
approved by the Institutional Review Board for Human
Subjects at the University of Nebraska-Lincoln. Plasma was
separated from blood cells by centrifugation (870×g for
30 min). Previous studies indicated that BTD precipitates
between 30% and 50% saturation with ammonium sulfate
[24]. Thus, for all experiments described here, plasma BTD
was precipitated using 30–50% saturation with ammonium
sulfate. Precipitated proteins, usually from 10 ml of plasma,
were resuspended in 1.5 ml of potassium phosphate buffer
(0.1 M, pH 6) and dialyzed for 24–36 h against three changes
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Fig. 1. Standard curve for colorimetric quantification of PABA. Absorbance
of derivatives of PABA was measured at 546 nm. The S.D.'s are too small to
be visible at low amounts of PABA (y=0.0013x+0.021; r=.998).

of 1 L of potassium phosphate buffer at 4°C. Dialyzed
samples were subdivided into 1-ml aliquots and stored at
−20°C. Please note that these crude preparations of BTD
might contain proteins that affect analysis of Vmax, Km, and
Ki. Individual aliquots were thawed and used as needed for
BTD assays as described below. The amount of protein was
quantified by using the Nanodrop 1000 spectrophotometer
(Wilmington, DE). Plasma BTD activity is known to vary by
about 25% among healthy individuals [25], explaining the
sample-to-sample variation described below.
2.2. BTD inhibitors
Putative inhibitors of BTD were synthesized by conjugating biotin to various allylamines using carbodiimide as the
coupling reagent. Briefly, equimolar amounts (0.21 mmol) of
D-biotin (50 mg), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (39 mg), 4-(dimethylamino)pyridine (25 mg) and allylamine derivatives (Table 1) were
dissolved in 5 ml of N,N-dimethylformamide in an 8-ml vial.
The solution was stirred under nitrogen atmosphere overnight. After the reaction was complete (checked by thin-layer
chromatography and stained with iodine or phosphomolybdic acid solution), DMF (N,N-dimethylformamide) was
evaporated under vacuum. The crude product was column
chromatographed on silica gel (Silica gel 60, 40-63 µm, EMD
Chemical; Gibbstown, NJ). The column was first washed
with 50 ml dichloromethane and the product eluted with
150 ml dichloromethane/methanol (10:1, by volume).
Solvents were removed by vacuum drying to obtain a white
solid powder product at a 40–90% yield. 1H and 13NMR was
used to verify the identity of the product.
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et al. [26] and Backman-Gullers et al. [27] and modified by
Nilsson and Ronge [28]. These protocols were adapted for
microtiter plates as follows. In a 96-well microtiter plate,
500 µg of partially purified BTD from plasma and 12 µl of
10 mM putative BTD inhibitors (120 nmol/well; 1.0 mM
final concentration) were mixed with 88 µl of 54 mM sodium
phosphate buffer (pH 6.0), containing 1.08 mM disodium
EDTA and 4.3 mM cysteamine hydrochloride (prepared
fresh); samples were preincubated at 37°C for 60 min. Then,
10 µl of 6 mM N-(+)-biotinyl-PABA (60 nmol/well; 0.5 mM
final concentration) was added to each well and plates were
incubated for 120 min at 37°C. Reactions were stopped by
adding 30 µl of 6 M hydrochloric acid and the following
compounds were added at 3-min intervals at room
temperature: 55 µl water, 15 µl of 14.5 mM sodium nitrite
(prepared fresh), 15 µl of 43.8 mM ammonium sulfamate,
and 15 µl of 3.86 mM N-1-naphtylethylenediamine dihydrochloride. Incubation was continued for 10 min. Precipitated proteins were removed by centrifugation (1260×g
for 10 min) and the supernatant was transferred to a new
plate and the absorbance was measured at 546 nm. Previous
studies suggested that BTD activity is maximal at 37°C and
pH 6.0 [24] and, thus, all tests were run under these
conditions. One unit of BTD activity is defined as the
amount of protein required to release 1 nmol of PABA
120 min−1 under the conditions of the assay.
2.4. Enzyme kinetics
Km, Vmax, and Ki [29] were determined as follows. The
concentration of inhibitors was kept constant (0.5 mM) in
enzyme assays as described above, while the concentration
of the substrate N-(+)-biotinyl-PABA was varied from
0.05 to 1 mM. The enzyme kinetics module of Sigmaplot
10.0 was used for calculations [30].

2.3. BTD assay
BTD activity was measured as the rate of hydrolysis of Nbiotinyl-4-aminobenzoic acid to release 4-aminobenzoic
acid (PABA). The latter was quantified using N-1-naphthylethylenediamine dihydrochloride as described by Knappe

Fig. 2. BTD activity depends on the concentration of its substrate, N-(+)biotinyl-4-amidobenzoic acid. BTD activity was monitored by the release of
PABA from N-(+)-biotinyl-PABA. The S.D.'s are too small to be visible
(y=0.11x−1.19; r=.989).
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Fig. 3. Hydrolysis of N-(+)-biotinyl-4-amidobenzoic acid (60 nmol/well)
depends on the amount of partially purified BTD. The S.D.'s are too small to
be visible (y=0.072x−1.03; r=.997).

2.5. Biotin transport
Theoretically, the biotin analogs tested here might affect
both biotin transport into human cells and BTD activity.
Here, biotin transport was quantified using a physiological
concentration of [3H]biotin (475 pM) in the presence or
absence of putative BTD inhibitors (0.5 mM) as described
[31]; the Km of biotin transporters is in the low micromolar
range [32]. Human Jurkat cells were used for biotin transport
studies [33].
2.6. Statistical analysis
Heterogeneous variances were identified by using
Bartlett's test, and data were log transformed where
applicable [34]. Significance of differences was tested by
one-way ANOVA. Fisher's protected least significant
difference procedure was used for post hoc testing. StatView
5.0.1 (SAS Institute, Cary, NC) was used to perform all

Fig. 4. Hydrolysis of N-(+)-biotinyl-4-amidobenzoic acid by partially
purified BTD is linear for up to 4 h. Values are means±S.D. (n=6). The S.
D.'s are too small to be visible.

Fig. 5. Biotinyl 2,4,6-trimethylbenzenamide (1 mM) does not inhibit BTD.
The effects of the treatment are not significantly different compared with
inhibitor-free controls. The incubation times denote the hour of incubation of
partially purified BTD, substrate and inhibitor. Values are means±S.D. (n=6;
PN.05).

calculations. Differences were considered significant if
Pb.05. Data are expressed as mean±SD.
3. Results
3.1. Calibration and linearity of the BTD assay
BTD activity was dependent on substrate concentration,
enzyme abundance and time. First, known amounts (0–
40 nmol) of synthetic PABA were used to generate a standard
curve (Fig. 1). This assay was linear up to 40 nmol PABA.

Fig. 6. Biotinyl-methyl 4-(amidomethyl)benzoate (1 mM) inhibits BTD.
Values are means±S.D. (n=6; ⁎Pb.05 compared with inhibitor-free control).
The incubation times denote the hour of incubation of partially purified
BTD, substrate, and inhibitor.
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Fig. 8. BTD activity is reduced in a substrate-concentration dependent
manner in the presence or absence of 0.5 mM of the inhibitor biotinylmethyl 4-(amidomethyl)benzoate.

Fig. 7. Biotinyl-methyl 4-(amidomethyl)benzoate inhibits BTD activity in a
concentration-dependent fashion. Values are means±SD (n=6). a,b,c,d Bars
not sharing the same letter are significantly different from the inhibitor-free
control (Pb.05).

Second, dependence of BTD activity on substrate concentration was quantified by incubating BTD with 0 (control),
0.1, 0.25, 0.5 and 0.75 mM of N-(+)-biotinyl-PABA per well
in a 96-well plate. PABA released from N-(+)-biotinylPABA reached a plateau at 0.5 mM of N-(+)-biotinyl-PABA
per well as judged by absorbance at 546 nm (Fig. 2); all
subsequent reactions were carried out using 0.5 mM of
N-(+)-biotinyl-PABA per well. Third, partially purified BTD
from plasma was added in increasing concentration: 0, 0.1,
0.2, 0.4, 0.5, 0.75 and 1 mg of protein per well. The assay
was linear up to a concentration of 1 mg of partially purified
BTD per well (Fig. 3). Fourth, a time course was conducted
to determine whether the hydrolysis of N-(+)-biotinyl-PABA
was linear with time. BTD and N-(+)-biotinyl-PABA were
incubated in assay buffer for up to 4 h after the addition of
0.5 mM of N-(+)-biotinyl-PABA at 37°C. The hydrolysis of
N-(+)-biotinyl-PABA was linear up to 4 h (Fig. 4); all
subsequent incubations with BTD were carried out for 2 h
following the addition of 60 nmol (0.5 mM final concentration/well) N-(+)-biotinyl-PABA unless otherwise noted.

3.2. Inhibitors of BTD
Seven of the 13 compounds tested here inhibited BTD. In
contrast, the following compounds did not significantly
affect BTD activity and were used as negative controls in
selected experiments: biotinyl diphenylamide, biotinyl
dibenzylamide, biotinyl (R)-1-(1-naphthyl)ethylamide, biotinyl 2,4,6-trimethylbenzenamide, biotinyl 3,4-dimethanilide
and biotinyl 4-amidobenzonitrile. These compounds had no
meaningful effects on BTD activity even if concentrations as
high as 0.5 mM were tested. The compounds tested here are
all biotin analogs, and it is highly unlikely that concentrations greater than 0.5 mM can be achieved in biological
fluids in vivo [35]. Fig. 5 depicts compound biotinyl 2,4,6trimethylbenzenamide as a representative example.
In contrast, the following compounds inhibited BTD
activity by more than 25%: biotinyl anilide, biotinyl allylamide, biotinyl N-methylanilide, biotinyl-methyl 4-(amidomethyl)benzoate, biotinyl 2-amido-pyridine, biotinyl

Table 2
Kinetics of BTD inhibitors
Inhibitor name

Kinetic variables
Vmax
Km
nmol min−1 mg−1 mM

Biotinyl methyl
4-(amidomethyl)benzoate
Biotinyl anilide
Biotinyl 2-amido-pyridine
Biotinyl allylamide
Data are means±S.D.

Ki
mM

0.29±0.001

0.04±0.0004 0.06±0.008

0.26±0.006
0.28±0.002
0.35±0.008

0.07±0.048
0.01±0.003
0.06±.002

0.26±0.183
0.27±0.011
0.09±0.011

Fig. 9. Lineweaver–Burk plot demonstrating competitive inhibition of BTD
by biotinyl methyl 4-(amidomethyl)benzoate. Vmax=0.29±0.009 nmol
min−1 mg−1; Km=0.04±0.007 mM; Ki=0.06±0.01 mM; n=3.
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4-amidophenylboronic acid and biotinyl benzylamide. Biotinyl-methyl 4-(amidomethyl)benzoate was the most effective
compound of all the inhibitors tested (Fig. 6). For example, if
BTD was incubated with N-(+)-biotinyl-PABA in the presence
of biotinyl methyl 4-(amidomethyl)benzoate for 30, 60 and
120 min, the hydrolysis of N-(+)-biotinyl-PABA was 80%,
59% and 30%, respectively, of inhibitor-free controls containing only dimethyl sulfoxide (DMSO). A greater percent
inhibition at earlier time points is an event frequently seen with
competitive inhibitors [29]. Importantly, the percent inhibition
of BTD increased if concentrations of inhibitors were
increased, consistent with competitive inhibition of BTD by
biotinyl methyl 4-(amidomethyl)benzoate (Fig. 7). For
example, if BTD was incubated with N-(+)-biotinyl-PABA
in the presence of 0.01, 0.1 and 1 mM biotinyl methyl
4-(amidomethyl)benzoate, the inhibition of hydrolysis of
N-(+)-biotinyl-PABA was 16%, 50% and 80%, respectively,
compared to inhibitor-free controls containing only
DMSO (Fig. 7).
Enzyme kinetics studies were conducted to confirm that
the biotin analogs tested here decreased BTD activity by
competitive inhibition. In these experiments we kept the
concentrations of inhibitors constant (0 vs. 0.5 mM) and
varied the concentrations of the substrate N-(+)-biotinylPABA (0.05–1 mM). For all the inhibitors tested, the percent
inhibition of BTD decreased if the concentration of N-(+)biotinyl-PABA was increased. Km and Vmax values were
consistent competitive inhibition (Table 2). The Ki value for
biotinyl methyl 4-(amidomethyl)benzoate was smaller than
Ki for all the other inhibitors, suggesting that this compound
has a greater affinity for BTD than the other compounds
tested (Figs. 8 and 9).
Finally, we determined whether biotinyl methyl 4-(amidomethyl)benzoate affected cellular biotin transport, potentially producing artifacts in future studies of BTD-mediated
chromatin biology at the cellular level. Biotin uptake into
Jurkat cells was quantified in the presence of excess biotinyl
methyl 4-(amidomethyl)benzoate, biotinyl anilide (specificity control) and DMSO (negative control). Biotinyl methyl
4-(amidomethyl)benzoate did not affect biotin uptake into
Jurkat cells compared with DMSO controls (13 ± 0.6 vs. 13 ±
0.9 amol×5×10−6 cells×30 min−1; PN.05; n=3), whereas
biotinyl anilide caused a significant decrease of biotin uptake
(5.4 ± 0.3 amol×5×10−6 cells×30 min−1; PN.05; n=3).

4. Discussion
Previous studies of BTD depended on using timeconsuming cuvette-based assays [26–28], making highthroughput screening of BTD inhibitors a tedious task. Here,
we present a 96-well plate assay that for the first time offers
the means for high-throughput screening of BTD activity and
putative BTD inhibitors.
Using this assay and an array of synthetic biotin
derivatives, we succeeded in identifying seven putative

BTD inhibitors. The most efficient compound was biotinylmethyl 4-(amidomethyl)benzoate that inhibited BTD up to
80% at a concentration of 1 mM. Our kinetics studies suggest
that biotinyl-methyl 4-(amidomethyl)benzoate (and other
compounds tested here) act by reversible, competitive
inhibition of BTD.
The inhibitors presented here are biotin derivatives and
are likely to primarily affect proteins involved in biotin
metabolism such as BTD, HCS and biotin transporters, as
opposed to affecting enzyme activity globally. Unspecific
inhibitors such as para-hydroxymercuribenzoate, hydroxylamine and mercaptoethanol do not offer the degree of
specificity needed for cell biology studies [8]. For example,
mercaptoethanol reduces sulfhydryl groups in enzymes,
causing conformational changes that affect enzyme activity.
Our studies on biotin transport provide evidence that some
BTD inhibitors do not affect biotin uptake, suggesting
specificity for BTD. We are currently in the process of
investigating effects of BTD inhibitors on other histone
biotinyl ligases such as HCS.
Note, however, that even if an inhibitor is specific for
BTD, it will abolish biological functions of this enzyme to
the same extent in various cell compartments. For example,
loss of BTD activity may result in biological changes
that could either be a result of decreased recycling of biotin
from breakdown products of carboxylases in the cytoplasm
[36] or of remodeling of chromatin through histone
debiotinylation in the nucleus [2]. Our first-generation
inhibitors of BTD do not overcome the problem of
specifically targeting cytoplasmic vs. nuclear BTD. A
second generation of BTD inhibitors is currently being
developed in our laboratory. The goal of these ongoing
studies is to create an inhibitor that specifically targets
nuclear BTD. Also, we will seek to modify these secondgeneration inhibitors so that they do not undergo significant
metabolism and loss of activity. Once these secondgeneration inhibitors become available, we hope to specifically characterize roles of BTD in chromatin remodeling.
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